Zimmer Biomet Holdings Inc (NYSE:ZBH) VP Chad F. Phipps sold 30,100 shares of Zimmer Biomet stock in a transaction on Friday, September 21st. The stock was sold at an average price of $132.37, for a total transaction of $3,984,337.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ZBH stock opened at $129.71 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.41 and a quick ratio of 1.25. Zimmer Biomet Holdings Inc has a 1-year low of $104.28 and a 1-year high of $134.55. The firm has a market cap of $26.56 billion, a price-to-earnings ratio of 16.15, a price-to-earnings-growth ratio of 2.39 and a beta of 1.09.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.04. Zimmer Biomet had a net margin of 21.67% and a return on equity of 13.53%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.99 billion. During the same quarter in the previous year, the company posted $2.08 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. equities research analysts predict that Zimmer Biomet Holdings Inc will post 7.66 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.74%. The ex-dividend date is Thursday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 11.96%.

Institutional investors have recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. raised its position in Zimmer Biomet by 5,200.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 988 shares in the last quarter. Adviser Investments LLC bought a new stake in Zimmer Biomet in the first quarter worth about $144,000. Aries Wealth Management bought a new stake in Zimmer Biomet in the second quarter worth about $202,000. Regent Investment Management LLC bought a new stake in Zimmer Biomet in the second quarter worth about $201,000. Finally, Azimuth Capital Management LLC bought a new stake in Zimmer Biomet in the second quarter worth about $201,000. Hedge funds and other institutional investors own 87.14% of the company’s stock.

A number of brokerages recently issued reports on ZBH. Argus lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Piper Jaffray Companies lifted their price target on shares of Zimmer Biomet from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. ValuEngine upgraded shares of Zimmer Biomet from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group lifted their price target on shares of Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $135.10.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Using the New Google Finance Tool

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.